Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Authorizes Quest Diagnostics SARS-CoV-2/Flu Test With Self-Collection Kit for Emergency Use

FDA Authorizes Quest Diagnostics SARS-CoV-2/Flu Test With Self-Collection Kit for Emergency Use

Dec 05, 2020
|
staff reporter

NEW YORK  – The US Food and Drug Administration on Friday evening granted Emergency Use Authorization for the first time to a diagnostic test for at-home, self-collection of patient samples for the detection of SARS-CoV-2 and influenza A/B.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Quick Changes If Needed

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Early Results on Johnson & Johnson's SARS-CoV-2 Vaccine

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

WHO Team Arrives

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

Nature Papers Present Amplicon Sequencing Approach, Dire Wolf Genomes

In Nature this week: a new method for high-throughput amplicon sequencing, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Issues Alert About Potential False Negative Test Results From SARS-CoV-2 Mutations

  2. FDA Grants Emergency Use Authorization for SML Genetree Molecular Coronavirus Test

  3. Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

  4. Helix Obtains FDA Authorization for Exome Sequencing Platform, Alzheimer's Disease Risk Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.